Skip to main content

Table 1 Patient characteristics

From: Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

  All patients (n = 20) Cytidine deaminase genotype subgroups
A/A (n = 8) A/C (n = 8) C/C (n = 4)
Gender (M/F) 17/3 8/0 6/2 3/1
Age (years) 65 (44–73) 67 (55–73) 65 (57–73) 59 (44–73)
Weight (kg) 77 (58–97) 81(60–97) 75 (58–87) 85 (63–88)
Length (cm) 175 (161–192) 177 (168–193) 173 (161–185) 182 (169–192)
BSA (m2) 1.93 (1.61–2.27) 2.00 (1.69–2.27) 1.90 (1.61–2.03) 2.09 (1.72–2.13)
Creatinine (μmol/l) 78 (49–119) 80 (60–119) 75 (49–99) 81 (66–92)
CrCl (ml/min) (normal: >60) 97 (51–134) 97 (51–130) 88 (64–106) 104 (59–134)
AST (U/l) (normal: <45) 22 (15–35) 22 (12–35) 22 (15–28) 21 (17–27)
ALT (U/l) (normal: <45) 27 (7–47) 23 (7–32) 29 (15–47) 26 (12–36)
Bilirubin (μmol/l) (normal: <20) 10 (6–17) 10 (6–16) 10 (6–17) 10 (9–11)
Co-treatment
Epirubicin 10 5 3 2
Cisplatin 10 3 5 2
  1. Values are medians with the ranges in parentheses